Directory
/ Search in the directory
Sylvie
Claeysen
IGF Sud 224
04 34 35 92 15Know more >
Sylvie
Claeysen
CRHC, Inserm
Team: Philippe Marin
EDUCATION
-
2009Habilitation to Supervise Research (HDR) - University of Montpellier - France
-
1999PhD - Biochemistry & Molecular Biology - University of Montpellier - France
-
1995Master's degree - Health Biology - University of Montpellier - France
POSITIONS HELD
-
2023-Senior Researcher at INSERM, Institute of Functional Genomics (IGF) - Montpellier - France
-
2002-2022Junior Researcher at INSERM, Institute of Functional Genomics (IGF) - Montpellier - France
-
2000-2002Postdoctoral fellow, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM) - Brussels - Belgium
HONORS / RESPONSABILITIES
- Awards
-
2024-2026Research and Doctoral Supervision grant (PEDR)
-
2020-2023Research and Doctoral Supervision grant (PEDR)
-
2016Member of the Inserm cross-cutting Program Microbiota
-
2013Junior Faculty Award - AD/PD™ 2013 - The Alzheimer's & Parkinson's Conference
-
2012Chercheuse d'avenir 2011 of the Languedoc Roussillon Region
-
2011Soroptimist International (French Union) Medal
-
2010France Alzheimer Research prize 2010
-
1997Roche Bioscience Prize - Advances in Serotonin Receptor Research, San Francisco, USA
- Duties
-
2023-Neuroscience representative on the Board of the BioHealth Department of Univ. Montpellier
-
2015-2023Scientific Board member of France Alzheimer association
-
2005-2010Elected member of the IGF Unit Council
-
1997-Member of the International Society for Serotonin Research (ISSR)
-
1997-Member of the French Neuroscience Society
- Editing
-
2020-Associate editor for Frontiers in Aging Neuroscience,
-
2019-Review editor for F. in Neuroscience & F. in Endocrinology
SKILLS / EXPERTISE
- My areas of expertise cover neuropharmacology, G-protein coupled receptors (GPCRs), serotonin receptors and neurodegenerative diseases. In connection with a network of clinicians, chemists, and biotech companies I propose innovative strategies to cure Alzheimer's disease (α-secretase activation, Multi-Targeted drugs, biomarkers), based on a deep knowledge of molecular and cellular mechanisms induced by GPCRs in neuroprotection.
- Member of the Inserm cross-cutting Program Microbiota, I currently explore the potential of gut microbiota modulation as a new therapeutic avenue against Alzheimer's disease.
